Skip to main content

Avascular Necrosis of the Talus

0
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Paragon 28
Paragon 28CO - Englewood
1 program
Patient Specific Talus SpacerN/A1 trial
Active Trials
NCT05364606Recruiting50Est. Nov 2029
restor3d
restor3dNC - Durham
1 program
Total Talus ReplacementN/A1 trial
Active Trials
NCT06311331Enrolling By Invitation50Est. Nov 2031

Trial Timeline

Clinical trial activity over time

2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
restor3dTotal Talus Replacement
Paragon 28Patient Specific Talus Spacer

Clinical Trials (2)

Total enrollment: 100 patients across 2 trials

NCT06311331restor3dTotal Talus Replacement

Prospective Evaluation of Clinical and Radiographic Outcomes Following Total Talus Replacement (PROCLAIM)

Start: Nov 2024Est. completion: Nov 203150 patients
N/AEnrolling By Invitation
NCT05364606Paragon 28Patient Specific Talus Spacer

Patient Specific Talus Spacer Post Approval Study

Start: Jul 2022Est. completion: Nov 202950 patients
N/ARecruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 100 patients
2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.